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A B S T R A C T
The aim of this work was to develop an innovative drug delivery system potentially useful for the local delivery
of Bisphosphonates to bone tissue. We propose the use of Solid Lipid Microparticles (MPs), up to now mainly
used for oral and topical drug delivery, as carrier for bisphosphonates due to the favourable biocompatibility and
lower toxicity of the lipids compared with many polymers. The delivery platform consisted of a biomimetic α-
tricalcium phosphate-gelatin cement (CPC) enriched with alendronate loaded MPs (MPs-AL) produced by the
spray congealing technology. Alendronate direct addition to cement composition is limited since Alendronate is
able to sequester calcium from calcium phosphates, thus preventing the setting of the cements. At variance, this
approach permitted to load a relatively high amount of the drug on the CPC and allowed the controlled release of
the highly water soluble alendronate. A Design of Experiment (DoE) was employed for the screening of the
eﬀects of the formulation variables related to the presence of unloaded microparticle (MPs) on the cement most
important mechanical properties. Then, MPs loaded with 10% w/w of alendronate were produced using ﬁve
diﬀerent carriers (Stearic Acid, Stearilic Alcohol, Cutina HR, Tristearin and Precirol ATO5). All MPs-AL exhibited
a spherical shape, encapsulation eﬃciency higher than 90% and prevalent particle size ranging from 100 to
150 μm. Solid state characterization (DSC, HSM and X-ray powder diﬀraction) demonstrated that encapsulation
of alendronate into MPs did not alter its crystal structure. MPs-AL addition to the cement provoked a modest
lengthening of the setting times and of the hardening reaction leading to the complete transformation of α-
tricalcium phosphate into calcium-deﬁcient hydroxyapatite, without signiﬁcantly aﬀect the cement mechanical
properties. Moreover, the results of in vitro AL release study performed on cements enriched with MPs-AL
showed that the system allows a controlled release of the drug over time.
1. Introduction
Calcium phosphate cements (CPCs) are biocompatibile and bioac-
tive materials, able to activate osteogenesis [1–4]. CPCs involve mixing
a solid phase with a liquid phase, which provides a mouldable paste
that stiﬀens during setting and hardening into a solid phase. As a
consequence, they are ideal materials for orthopedic implants that can
perfectly ﬁt to a bone cavity. Bone healing process is promoted by CPCs
resorption, which can occur via direct action of bone cells and/or
through chemical dissolution/hydrolysis in the body ﬂuids [5]. The
solid phase of CPCs is constituted of one or several calcium phosphates,
whereas the liquid phase is often water or a phosphate solution. Since
the development of the ﬁrst CPC formulation [6], a variety of diﬀerent
compositions has been proposed and the role of a number of parameters
on the properties of the cements has been investigated [4,7–9].
Brushite, (CaHPO4·2H2O, DCPD), and hydroxyapatite, both in the
stoichiometric form (Ca10(PO4)6(OH)2, HA) or as calcium-deﬁcient
hydroxyapatite (CDHA) are the possible end members of the cementi-
tious reaction [10].
Most apatitic CPCs relies on the hydrolysis of α-tricalcium
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2phosphate (α-TCP) powder that constitutes the main component of the
solid phase and yields an apatitic phase similar to the biological one as
result of the hardening process in an aqueous environment at 37 °C
[11]. The not exhothermic setting reaction of CPCs has several ad-
vantages, including the possibility to load biological molecules and
drugs. The possibility to use CPCs as drug delivery systems has been
tested through combination of the drugs with the solid or liquid phase,
or through introduction in a particulate carrier added to cement for-
mulation [13]. Antibiotics, anti-inﬂammatory agents, anti-osteoporotic
and anticancer drugs, growth factors and proteins are the main cate-
gories of substances which have been included in the composition of
CPCs [12–14]. In particular, calcium phosphate cements have been
proposed to deliver bisphosphonates (BPs) to the target sites in order to
overcome the problem of poor availability of these drugs, as well as to
minimize the side eﬀects provoked by their systemic administration
[14,15]. BPs are potent drugs for the treatment of pathologies char-
acterized by excessive osteoclast mediated bone resorption, such as
osteoporosis, Paget’s disease and bone metastases, and have also been
suggested as potential anticancer agents [16,17]. BPs inclusion in CPCs
was obtained through addition to the liquid phase or chemisorption on
one of the component of the solid phase [18–21]. The presence of BPs
was generally found to lengthen the setting time and decrease com-
pressive strength of the cement [18,21–24].
The use of biodegradable microspheres has been proposed to load
other substances, such as growth factors and antibiotics, and also to
increase the porosity of the CPCs [25–30]. The most used materials for
this purpose are poly(DL-lactic-co-glycolic acid) (PLGA) [26–28,30,31]
and gelatin [32,33]. In particular, it was shown that encapsulation of
vancomycin in PLGA microspheres provided a longer sustained release
with respect to loading the drug in the cement powder [31]. It is con-
ceivable to hypothesize that the use of microparticles (MPs) as drug
carriers inside CPCs should avoid/limit the lengthening of setting times
caused by substances like bisphosphonates and also provide a tailored
sustained release. Herein, we investigate the possibility to use solid
lipid microparticles as carrier for bisphosphonates due to the favourable
biocompatibility and lower toxicity of the lipids compared with many
polymers [34]. Solid lipid MPs can be produced using diﬀerent tech-
nologies such as melt dispersion technique, solvent evaporation, hot
and cold homogenization, spray drying and spray congealing [34]. In
this work, the spray congealing technique has been selected as it does
not require the use of organic or aqueous solvents and hence it is en-
vironmentally friendly and less time consuming than other methods
[35]. In addition, the spray congealing technology avoids the use of
surfactants and it is easily scaled-up. The aim of the work is to design
and develop an eﬃcient drug delivery system able to load relatively
high amount of sodium alendronate into the calcium phosphate ce-
ments, while maintaining suitable cement mechanical properties. In
particular the delivery platform consists of CPC enriched with Solid
Lipid MPs. As numerous formulation parameters related to the MPs can
(negatively) inﬂuence the CPCs characteristics, we ﬁrstly applied a
Design of Experiment (DoE) for the evaluation of the eﬀect of types,
dimensions and amount of unloaded MPs on the CPCs most important
mechanical properties. Then the study was performed using ﬁve dif-
ferent types of excipients to prepare MPs loaded with alendronate and
added to the composition of a biomimetic gelatin-α-TCP cement. The
setting and hardening properties of the cements were investigated as a
function of the presence of alendronate. In addition, in vitro sodium
alendronate release study were performed on AL-loaded Solid Lipid
MPs and on cement enriched with AL-loaded MPs.
2. Materials and methods
2.1. Microspheres
2.1.1. Preparation of microparticles (MPs) and of alendronate-loaded
microparticles (MPs-AL)
For the production of the microparticles, ﬁve diﬀerent excipients
were tested: Stearic Acid, Stearilic Alcohol, Cutina HR (hydrogenated
castor oil) and Tristearin were purchased from Farmalabor S.R.L., Italy,
while Precirol ATO5 (Glyceryl palmitostearate) was kindly supplied by
Gattefossè, France. The microparticles were produced by the spray-
congealing process using the wide pneumatic nozzle (WPN), which is an
external-mix two-ﬂuid atomiser already described in detail in previous
work [36]. For the preparation of the MPs and MPS-AL, the excipient
was heated at a temperature of 10 °C above its melting point. Alen-
dronate sodium trihydrate (AL) (ChemOs GmbH Germany), when pre-
sent, was added to the molten excipient and stirred to obtain a homo-
geneous suspension which was then loaded into the feeding chamber of
the WPN. The batch size was 20 g. Two WPN operating parameters can
be set: the pressure of the inlet air and the temperature of the device. In
the preliminary studies for the production of MPs, the atomisation was
carried out setting the air pressure at 3.5 bar and heating the WPN at
three diﬀerent temperature (50, 60 and 70 °C). Then, MPs-AL were
obtained with the air pressure at 3.5 bar and the nozzle temperature at
70 °C. The atomisation of the molten ﬂuid led to the formation of
melted droplets which then solidiﬁed during the fall in the cooling
chamber held at room temperature. The ﬁnal MPs were collected, size
separated and stored in polyethylene closed bottles at 4 ± 2 °C.
2.1.2. MPs characterization
2.1.2.1. Particle size and morphological analysis. The size distribution of
MPs was evaluated by sieve analysis, using a vibrating shaker (Octagon
Digital, Endecotts, London, UK) and 6 standard sieves (Scientiﬁc
Instruments s.r.l., Milano, Italy) of 50, 75, 100, 150, 250 and 500 μm.
The MPs were observed by using a scanning electron microscope
ESEM Quanta 200 (FEI, Cambridge, UK) at 10.0 kV accelerating voltage
without any coating.
2.1.2.2. Determination of drug content. 40 mg of MPs-AL were
accurately weighted and added to 10 mL of PBS pH 7.2. The
suspensions were heated 10 °C above each excipient melting point to
melt the carrier and gently shaken for 60 min. The solution was ﬁltered
and the drug content was assayed by a spectrophotometric method
[37], that requires the use of a derivatizing agent. Brieﬂy, a working
solution of the derivatizing reagent was prepared by dissolving 12.5 mg
of anhydrous ortho-phthalaldehyde (OPA, Sigma-Aldrich) in 2 mL of
PBS, then 62.5 mL di 2-Mercaptoethanol (ME, Sigma-Aldrich) solution
were added and the ﬁnal volume of 25 mL obtained by adding PBS. This
solution was freshly prepared before each experiment. For the
calibration curve, proper aliquots of AL standard solution (1mg/mL in
PBS) were mixed with 2 mL of derivatizing solution and 0.25 mL of
NaOH 5M and the volume ﬁlled up to 25 with PBS in order to obtain a
concentration of AL ranging from 5 to 100 mg/mL; the absorption was
measured at 330 nm (R2 = 0.9978).
Each formulation was analyzed in duplicate and the mean ± SD
was reported. Finally, the encapsulation eﬃciencies (EE) were calcu-
lated as follows:= ×EE (%) (Wa/Wt) 100
where Wa is the actual drug content and Wt is the theoretical drug
content.
2.1.2.3. MPs-AL dissolution studies. In vitro dissolution tests of MPs-AL
were performed in PBS pH 7.2 at a temperature of 37 °C. For each
sample 40 mg of MPs were poured into 10 mL of PBS under continuous
stirring (50 rpm). As the AL is very soluble in water (10 mg/mL, Sigma
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3Aldrich data), sink conditions (concentration C < 0.2 solubility Cs)
were assured. The solution was withdrawn at pre-determined time
intervals up to 4 h using a 0.40 μm poroplast ﬁlter in order to separate
the microparticles from the buﬀer and a fresh buﬀer solution (10 mL)
was added. The amount of drug dissolved was analyzed via
spectrophotometer at 333 nm (UV2 Spectrometer, Unicam,
Cambridge, UK) using the method reported in the Determination of
drug content section [37]. The dissolution tests were performed at least
in triplicate and the mean ± SD was reported.
2.1.2.4. Diﬀerential scanning calorimetry (DSC) studies. DSC
measurements were performed using a PerkinElmer DSC 6
(PerkinElmer, Beaconsﬁeld, UK). The samples, weighing 8–12 mg,
were placed into the DSC under a nitrogen ﬂux (20 mL/min) and
heated from 25 °C to 300 °C at a scanning rate of 10 °C/min. For
comparison, the same procedure was followed for the raw materials.
Each analysis was carried out in duplicate.
2.1.2.5. X-rays diﬀraction studies. MPs and MPs-Al were packed into
recessed silicon slides and subjected to X-ray diﬀraction analysis by
means of a Philips X'Celerator powder diﬀractometer equipped with a
graphite monochromator in the diﬀracted beam. CuKα radiation was
used (40 mA, 40 kV). The spectra were obtained in the 4–40° 2θ range
using a 0.067° step and a 3°/min speed.
2.1.2.6. Hot stage microscopy (HSM) analysis. Hot-stage microscopy
(HSM) was carried out on hot stage apparatus (Mettler-Toledo S.p.A.)
mounted on Nikon Eclipse E400 optical microscope connected to a
Nikon Digital Net Camera DN100 for the image acquisition. The
samples were heated at 25 °C for 1 min for equilibration and then
heated from 25 °C to 20 °C above the melting point of each excipient at
a scanning rate of 10 C/min.
2.2. Cements
2.2.1. Preparation of cements (CPCs)
Starting cement powders, made of α-TCP and 15 wt% of gelatin
(type A from pig skin, Sigma Aldrich) were obtained as previously de-
scribed [8], crushed in an electric mortar and sieved (< 40 μm).
Weighted amounts of the starting powders were mixed with DCPD
(CaHPO4·2H2O), following the procedure reported in [8], and the ce-
ment pastes were obtained inside Teﬂon moulds after addition of
Double Distilled Water (DDW), using a liquid to powder ratio of
0.22 mL/g. Just after mixing CPCs were compacted by using a 4465
Instron dynamometer set at 80 N for 1 min, demoulded and then im-
mersed in Phosphate Buﬀer (PB), pH = 7.4, at 37 °C for diﬀerent
periods of time up to 21 days.
These cements are used as a control. Some samples containing a
suitable amount of Alendronate, dispersed as powder into the starting
materials, were also prepared.
2.2.2. Preparation of CPCs containing MPs and MPs-AL
In order to obtain the microspheres-containing CPC, weighted
amount of MPs were added to the cement powders before mixing with
the liquid phase. Cements containing 1, 5 and 7 wt% of MPs were
prepared following the same procedure described above and stored in
PBS until 21 days. The cements were labeled CPCs-MPs.
The MPs-AL-containing cements were synthesized by using
Alendronate loaded microspheres of selected dimensions, ranging be-
tween 100 and 150 μm. The cements were prepared as described above
and labeled CPCs-MPs-AL.
2.2.3. Characterization
2.2.3.1. Setting times determination. Initial and ﬁnal setting times were
determined by the Gillmore method (ASTM, American Society for
Testing and Materials: C 266-89. Standard test method for time of
setting of hydraulic cement pasteby Gillmore needles). Initial and ﬁnal
setting times were determined by the Gillmore method (ASTM,
American Society for Testing and Materials: C 266-89. Standard test
method for time of setting of hydraulic cement pasteby Gillmore
needles). The apparatus consists of two horizontal arms, which carry
two weighted steel needles: the needle used to determine initial setting
time (ti) weighs 113 g and is 2.12 mm of diameter, while that used for
the determination of ﬁnal setting time (tf) weighs 453.6 g and is
1.06 mm of diameter. The values of ti and tf are expressed in minutes
measured from the beginning of mixing. The paste was considered set
when the needle doesn’t provoke any visible indentation on the cement
surface.
2.2.3.2. Mechanical properties. Mechanical characterization was
performed on the cylindrical specimens (6 mm in diameter and
12 mm high) after 1, 3, 7 and 21 days of soaking in PBS. A 4465
Instron testing machine, equipped with a 1 kN load cell, was used. At
least six specimens for each incubation time were tested at a crosshead
speed of 1 mm/min.
2-ways analysis of variance (ANOVA) was employed to assess sta-
tistical signiﬁcance of the results. The signiﬁcance was performed with
a Bonferroni posttests. The diﬀerence was considered statistically sig-
niﬁcant with a p-value< .05.
2.2.3.3. X-rays powders diﬀraction. For X-ray diﬀraction analysis the
cements were extracted from PBS, at selected times, and immediately
immersed in liquid nitrogen for 10 min, in order to stop the hardening
reaction. The samples were then ground in a mortar, packed into
recessed silicon slides and subjected to X-ray diﬀraction analysis by
means of a Philips X'Celerator powder diﬀractometer equipped with a
graphite monochromator in the diﬀracted beam. CuKα radiation was
used (40 mA, 40 kV). The spectra were obtained in the 4–45° 2θ range
using a 0.067° step and a 3°/min speed.
The relative amount of α-TCP conversion into calcium deﬁcient
hydroxyapatite (CDHA) was determined through the measurement of
the integrated intensities of the reﬂections at 25.9_ and 24.3_ of 2θ,
corresponding to the 002 reﬂection of hydroxyapatite and to the 131
reﬂection of α-TCP, respectively. The amount of CDHA in the samples
was determined from the ratio of the integrated peak areas expressed as
A002/(A002 + A131), using a calibration curve obtained from weighted
mechanical mixtures of hydroxyapatite and α-TCP.
2.2.3.4. Morphological analyses. Morphological investigation of the
fractured surfaces of the cement samples was performed using a
Philips XL-20 Scanning Electron Microscope. The samples were
sputter-coated with gold prior to examination.
2.2.3.5. Alendronate release from CPCs-MPs-AL studies. In vitro
dissolution studies were performed for CPCs made with MPs-Cut-AL
and MPs-Pre-AL-using PBS pH 7.2 at a temperature of 37 °C. For each
test, two weighted cements were immersed into 5 mL of PBS. The
solution was withdrawn at pre-determined time intervals up to 21 days
and fresh buﬀer solution (5 mL) was added. The buﬀer solution was
ﬁltered (0.2μm) and its drug content was determined via
spectrophotometric analysis at 333 nm (UV2 Spectrometer, Unicam,
Cambridge, UK). The dissolution tests were performed at least in
triplicate and the mean ± SD was reported.
2.2.3.6. Experimental design. The screening of the eﬀects of the MPs
loading inside the CPCs was planned using a Design of Experiments
(DoE). In particular, an asymmetrical factorial design was considered to
evaluate the inﬂuence of three MPs characteristics (called independent
variables) on the most important CPCs mechanical properties
(dependent variables or experimental responses). For the runs of the
DoE, unloaded MPs were employed. Table 1 shows the levels of the
three selected independent variables (Xi). As dependent variables, the
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4following CPCs properties were selected: the compressive strength (Y1),
the elastic modulus (Y2) and the conversion of a-TCP into CDHA (Y3).
Each dependent variable was measured at four diﬀerent soaking times
(1, 3, 7 and 21 days).
The experimental plan (Table 2) was then designed using NEM-
RODW software [38]. The standard run order of the 15 diﬀerent ex-
periments was completely randomised to reduce the eﬀect of external
(uncontrolled) factors.
The eﬀect of the variation of the independent variables Xi on the
experimental responses Yi was then studied and the data processing was
carried out using NEMRODW software.
3. Results and discussion
Factors controlling Calcium Phosphates Bone Cements setting and
hardening is negatively inﬂuenced by a lot of additives, including those
able to improve biological performance of the cement itself. A suc-
cessful method proposed to passivate additives and inhibit direct con-
tact with the cement is the use of microspheres, usually made of
polymeric materials, like PLGA and gelatin. In this work, we explore the
possibility to enrich CPCs formulation with Solid Lipid Microparticles,
up to now used mainly for oral and topical drug delivery, as vehicles for
controlled release of API. In order to verify the capability of this com-
posite system, we chose sodium alendronate as API, since it is known
that the incorporation of bisphosphonates into the cement powders is
hindered by their high aﬃnity for calcium [18], which prevents the
setting of the cements and the hardening reaction. In a previous work
[19], we have demonstrated that sodium alendronate can be added as
powder to the cement formulation up to a maximum amount of 0.2%
wt. The results of our new study demonstrate that the multi-composite
system permits to enhance this value, since it avoids the interaction
between the drug and the cement and provides a controlled release of
the high water soluble drug AL. A representation of the experimental
approach followed in this work was illustrated in Scheme 1. Unloaded
MPs produced from ﬁve diﬀerent excipient were obtained by the spray
congealing technique and fully characterized in terms of dimensional,
morphological and structural properties, and added to the cement
composition following the Experimental Plan reported in Table 2. On
the basis of DoE results the type of excipient, dimensions and amount of
MPs to be added to CPCs were selected and a new set of MPs, containing
a proper amount of alendronate, was produced and added to the CPCs
formulation.
3.1. MPs production
The MPs production was optimized as a function of nozzle tem-
perature, as described in Section 2. All the obtained microspheres ap-
peared round-shaped with a smooth surface and the distribution of their
dimensions shows a Gaussian proﬁle with slightly diﬀerences as a
function of temperature. Fig. 1 reports, as an example, the SEM images
recorded from MPs-Cut along with the particle size distribution: the
microspheres appeared round-shaped with a smooth surface (ﬁgure a,
b) with the prevalent particle size ranging from 100 to 150 μm (Fig. 1c).
The range from 100 to 150 μm is that prevalent for all the formulations,
except for Stearylic Alcohol where the prevalent fraction is that from 75
to 100 μm (see Fig. S1). A complete characterization of the produced
MPs was carried out, and the results will be discussed shortly as a
comparison with MPs-AL in Section 3.3.
Table 1
Experimental domain.
Factor Associated variable No. of levels Levels
MPs percentage 3 1%
X1 5%
7%
MPs size 3 50 μm
X2 75–100 μm
100–150 μm
Type of excipient 5 Stearylic alcohol
Stearic acid
X3 Tristearin
Precirol® ATO5
Cutina® HR
Table 2
Experimental plan.
No. of
Experiments
Random
order
% MPs Dimension (μm) Type of
excipient
1 2 1 50 Stearylic
alcohol2 1 5 75–100
3 16 7 100–150
4 17 1 50 Stearic acid
5 15 5 75–100
6 18 7 100–150
7 6 1 75–100 Tristearin
8 3 5 100–150
9 5 7 50
10 8 1 100–150 Precirol ATO5
11 11 5 50
12 12 7 75–100
13 7 1 75–100 Cutina HR
14 14 5 100–150
15 13 7 50
Scheme 1. Schematic of the experimental approach.
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5Fig. 1. Characterization of MPs-Cut. (a, b) SEM images of microspheres at two diﬀerent enlargements. (b) is mixed signals from secondary electrons and back-scattered electrons. Scale
bars: a = 100 μm; b = 25 μm. c: Particle size distribution of MPs-Cut. Diﬀerent colors indicate diﬀerent nozzle temperature.
Fig. 2. SEM images of CPC-Cut; the bar represents 100 μm.
Fig. 3. Total eﬀects of the three factors, each considered at diﬀerent level, on the three chosen experimental responses (***p = .001, **p = .01, *p = .05). Factor 4 was included to assess
the “time eﬀect” (after 1, 3, 7 and 21 days).
Fig. 4. Characterization of MPs-Cut-AL. SEM images of: (a, b) micro-
spheres at two diﬀerent enlargements; (c) commercial AL crystals. (b)
is mixed signals from secondary electrons and back-scattered electrons.
Scale bars: a = 100 μm; b = 25 μm; c = 10 μm. (d) Particle size dis-
tribution of MPs-Cut-AL.
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63.2. Development of cements by use of experimental design
The screening of the eﬀects of the formulation variables related to
the presence of MPs inside the CPCs was planned using a Design of
Experiments (DoE) and their inﬂuence on the CPCs properties was
evaluated. This approach allows to obtain the highest amount of in-
formation reducing the number of the experiments and to avoid
misleading conclusions that can be drown with a traditional experi-
mental approach (simple trial and error varying one factor at a time)
[39]. Three independent variables (Xi) were considered at diﬀerent
levels (Table 1): the percentage of MPs loaded in the CPCs (X1 at 3
levels), the MPs size (X2 at 3 levels) and the type of excipients, selected
among the lipid used as carriers in the spray congealing technique (X3
at 5 levels). Three critical CPCs properties were considered as depen-
dent variables (Yi, experimental responses): the compressive strength
(Y1), the elastic modulus (Y2) and the conversion of a-TCP into CDHA
(Y3). Each dependent variable was measured at diﬀerent soaking times
(1, 3, 7 and 21 days). Furthermore, the initial and ﬁnal setting times
were recorded and morphological observations of the cements fractured
surfaces were performed.
In order to obtain a cement paste containing well-dispersed micro-
spheres, the excipients were added to the cement powders and mixed in
an electric mortar for 60 s before addition of the liquid phase. Fig. 2
reports an image obtained from CPC-Cut: it can be inferred that the
microspheres were homogeneously distributed along the whole surface.
Fifteen diﬀerent cement compositions, corresponding to the random
order reported in Table 2, were prepared and analyzed according to the
DoE approach. To quantify the “weight” of every level of the in-
dependent variables here considered, the experimental data were pro-
cessed by means of a multilinear regression model deﬁned in terms of
an arbitrary reference state. For a better interpretation of the inﬂuence
of the diﬀerent variable levels on the CPCs-MPs properties under study
(Yi), a graph-mode representation was used.
In Fig. 3, where the “total weights” graphs are shown, the highest
level of each factor is taken as the level unit measure for each single
factor. Therefore, all the highest factor levels (red bars) are represented
with the same length. This graphical procedure enables the visualiza-
tion and the simultaneous comparison of level eﬀects on the dependent
variables (Yi). Thus, the factor levels that remarkably inﬂuence the ﬁnal
result can be easily identiﬁed [40]. In particular, in this study it is
important to maximize all the considered experimental responses. For
the data analysis, in order to assess the eﬀect of soaking time on the
three dependent variables, four diﬀerent times (1, 3, 7 and 21 days)
were considered as levels of a further “experimental” factor.
The results of the inﬂuence of Xi on the variable Y1 (the CPCs-MPs
compressive strength) (Fig. 3A) showed that the percentage of MPs (X1)
inﬂuenced Y1: in particular, the 7% of MPs signiﬁcantly decreased Y1
respect to 1%. The MPs size (X2) and the type of excipient (X3) had not a
signiﬁcant eﬀect on Y1. As expected, the soaking time had a great in-
ﬂuence on the CPCs-MPs compressive strength: the value of Y1 after 3
days is not signiﬁcantly diﬀerent from 1 day, while the diﬀerence be-
tween 3 and 7 days would seem to be more relevant (even if not sta-
tistically signiﬁcant in this case). This eﬀect is probably due to the
complete conversion of a-TCP into CDHA, which take place for all the
tested compositions after 7 days. Quite similar trends were observed
(Fig. 3B) for the experimental response Y2 (CPCs-MPs elastic modulus):
Fig. 5. DSC curves recorded on Cut-based samples.
Fig. 6. Powder X-rays diﬀraction patterns of: (a) AL; (b) Cut; (c) MPs-Cut; (d) MPs-Cut-
AL.
Table 3
Initial and ﬁnal setting times measured for MPs- and MPs-AL cements.
Excipient CPC-MPs CPC-MPs-AL
ti (min) tf (min) ti (min) tf (min)
Stearylic alcohol 4 ± 1 10 ± 1 7 ± 1 14 ± 1
Stearic acid 3 ± 1 6 ± 1 6 ± 1 14 ± 1
Tristearin 5 ± 1 8 ± 1 6 ± 1 12 ± 1
Precirol® ATO5 4 ± 1 6 ± 1 6 ± 1 10 ± 1
Cutina® HR 3 ± 1 5 ± 1 4 ± 1 6 ± 1
none 2 ± 1 5 ± 1 nd nd
Fig. 7. Eﬀect on cement pastes cohesion of 0.5% of AL directly dispersed into the starting
powders (left) and loaded with -MPs-Cut-AL (right).
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7by increasing the amount of MPs from 1% to 7%, Y2 decreased sig-
niﬁcantly, while the MPs size was an irrelevant variable. As regards
excipient type, Stearylic alcohol would seem to increase the CPCs-MPs
elastic modulus in comparison to Precirol ATO5. As regards the ex-
perimental response Y3 (conversion of a-TCP into CDHA), the graphs in
Fig. 3C show that the variables percentage of MPs, MPs size and ex-
cipient type were not relevant. As expected, the soaking time sig-
niﬁcantly inﬂuenced this dependent variable till 7 days.
The results of the explorative analysis indicated that it is possible to
load lipid MPs inside the CPCs maintaining suitable cement mechanical
properties. Increasing the amount of empty MPs loaded into the CPCs
from 1% to 7% signiﬁcantly decreased both the CPCs compressive
strength and elastic modulus, while the MPs size and the type of ex-
cipient did not aﬀect the CPCs mechanical properties.
Therefore, in the subsequent part of the work, a 5% of MPs and of
MPs-AL, prepared using all the 5 carriers, were embedded into CPCs
formulation and a complete characterization of the cement properties
was carried out.
3.3. Characterization of MPs and MPs-AL
The incorporation of drug (10% w/w) did not alter the size dis-
tribution (see Fig. S2) and the spherical shape of the microparticles,
which still appeared round-shaped with a smooth surfaces. As an ex-
ample of AL loaded microparticles, Fig. 4 reports the SEM images re-
corded on commercial AL and on MPs-Cut-AL, together with the par-
ticle size distribution. SEM analysis of the drug (Fig. 4c) showed that
the commercial AL crystals had an irregular shape with length between
5 and 30 μm. The incorporation of drug (10% w/w) did not alter the
spherical shape of the microparticles, which still appeared round-
shaped with a smooth surfaces (Fig. 4a and b), and the size distribution
(Figs. 4d and S2).
In order to detect possible drug or carrier modiﬁcation due to the
spray congealing process or to interaction between AL and the ex-
cipients, the microspheres were analyzed by means of DSC and X–ray
diﬀraction. Fig. 5 reports the DSC curves of the raw excipient Cutina HR
(Cut), of the corresponding microparticles with and without AL (MPs-
Cut-AL and MPs-Cut, respectively) and of Cut and AL physical mixture
(Mix). The DSC curve of pure AL presents two endothermic peaks: an
Fig. 8. Powders X-Rays diﬀraction patterns of: (a) CPC-Cut and (b) CPC-Cut-AL after diﬀerent times of soaking. The arrow indicates 002 reﬂection of CDHA, while the asterisks indicate
some characteristic reﬂections of α-TCP.
Fig. 9. Relative amount of CDHA content as a function of soaking times, for cements
containing MPS (a) and MPsAL (b).
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8irregular peak with shoulders centered at 133.38 °C, and a peak at
266 °C, which correspond, respectively, to loss of structural water, and
to the melting process of the drug [41]. These peaks are clearly ap-
preciable in the thermogram of MPs-Cut-AL, together with the peaks
due to excipient melting.
Comparing the thermograms obtained from MPs-Cut-AL and from
the corresponding physical mixture, no diﬀerences were evidenced,
suggesting that the spray congealing process did not modify the solid
state of the drug and of the carrier.
Similar results were obtained for the MPs and MPs-AL prepared with
the other excipients, except for tristearin microparticles, as shown in
Fig. S3. It is well known that triglycerides can crystallize in at least
three polymorphic forms: the least thermodynamically stable α form,
the metastable βI form and the stable β form. DCS curves of tristearin
revealed a single endothermic peak at 75.5 °C attributable to the
melting of stable β form. The thermogram of AL-Tristearin physical
mixture presented the original characteristic peaks of the carrier and of
the drug. On the contrary, the DSC curves of both empty and AL-loaded
MPs evidenced the endothermic peak of the α form at 60.3 °C, followed
by the exothermic peak of the recrystallization of the α form into the β
form and by the melting of β form. In addition, DSC of AL-loaded MPs
presented the two characteristic endothermic peaks of AL, suggesting
the permanence of the drug in its original crystalline form. These results
suggested that the rapid cooling from the melt which occurred during
the spray congealing process resulted in a transformation from the
original tristearin stable form into a diﬀerent polymorph, according to
data reported in literature [42].
Additional information on the solid state structures of the drug and
the carriers were obtained through X–ray diﬀraction analysis. Fig. 6
reports the XRD patterns of the raw excipient (Cutina HR), that showed
the characteristic reﬂections at 5.2, 19.5 and 21.95° of 2θ, together with
those of AL (PDF 00-050-2301), MPs-Cut and MPs-Cut-AL. The XRD
pattern of Cut compared to that of MPs-Cut doesn’t show any diﬀer-
ences, revealing no structural changes after the spray congealing pro-
cess, while the MPs-AL shows the characteristic diﬀraction peaks of
alendronate together with those characteristic of the excipient. XRD
spectra were recorded for all the excipients and reported in Fig. S4. No
diﬀerences were found for all the excipient, except for Tristearin which,
according to obtained DSC proﬁles, clearly shows a diﬀerent diﬀraction
pattern before and after spray congealing, due to a diﬀerent polymorph
formation.
In addition, the HSM analyses on the MPs-AL obtained from all the
excipients were performed and reported in S5. In all the samples,
crystals of AL were clearly evidenced after the fusion of the low-melting
excipients, conﬁrming the permanence of the drug in its crystalline
structure after the spray congealing process.
3.4. CPCs-MPs-AL characterization
As the MPs sizes were not relevant for the CPCs properties, the MPs
dimensions were selected in the range 100–150 μm, which was the
prevalent fraction for the majority of the excipients (see Fig. S2). The
amount of AL loaded into MPs-AL was 10%, which means that AL
content in the cements corresponds to 2.5-fold the maximum amount
previously inserted in CPCs [19].
The analysis of the drug content of the MPs evidenced that, in-
dependently from the excipient, the actual AL contents were close to the
theoretical values (10% w/w) for all the formulations, allowing to ob-
tain encapsulation eﬃciency (EE) values higher than 90%. These results
are consistent with those reported in previous studies [35,36], con-
ﬁrming the usefulness of the spray congealing as technology to eﬃ-
ciently incorporate drugs into the matrix of MPs.
Two diﬀerent controls were used: CPCs and CPCs-MPs
(100–150 μm, 5% w/w). Table 3 reports the initial and ﬁnal setting
times for all the MPs- and MPs-AL cements, and for the reference
samples.
We have previously demonstrated [18,19] that the presence of bi-
sphosphonates increases the setting times of the cements and that AL
contents greater than 0.2% (w/w) prevent setting. In the present study,
the setting times of CPC-MPs are only slightly diﬀerent with respect to
CPC (Table 3), thus evidencing that the addition of Solid Lipid Micro-
particles doesn’t interfere with the setting process. When cements are
loaded with AL-containing microparticles, the setting times are still
comprised into the interval of clinical interest. However, the values are
comparable to those of the CP-MPs when Precirol And Cutine are used
as excipients, whereas longer setting times are observed for Stearylic
alcohol, Stearic Acid and Trystearine. This result suggests that the ap-
proach used here is successful and allows the incorporation of a rela-
tively high amount of Sodium Alendronate. In fact, adding the same
amount of AL as that loaded into MPs directly to the starting cement
powders, prevents setting and cohesion of the paste, as showed in
Fig. 7.
The X-ray diﬀraction patterns of the cements collected after dif-
ferent soaking times in PB are reported in Fig. 8 and showed the re-
ﬂections due to α-TCP together to those characteristic of poor crystal-
line hydroxyapatite (CDHA): some of the most representative
reﬂections of both phases are indicated.
The diﬀraction patterns recorded on CPC-Cut (Fig. 8a) and on CPC-
Cut-AL (Fig. 8b), show that the conversion of the starting powders into
CDHA was complete after seven days of soaking for the cement con-
taining MPs, whereas the presence of Alendronate, loaded into the MPs,
delayed the conversion and a small amount of a-TCP was still detectable
after 21 days. A similar trend was observed for all the formulations. The
extent of conversion of α-TCP into CDHA as a function of soaking time
has been evaluated from the powder X-ray diﬀraction patterns using the
calibration curve obtained through the analysis of the diﬀraction pat-
terns of weighted mechanical mixtures of hydroxyapatite and α-TCP, as
reported in Section 2. The results plotted in Fig. 9 put into evidence that
the conversion of α-TCP is delayed in the MPs-AL containing cements
and proceed to a maximum extent of about 90% after 21 days of
soaking when Pre, Cut and Aci are employed as excipients.
The values of compressive strength, σb, of the cements at diﬀerent
Table 4
Compressive strength (σb), of the diﬀerent samples as a function of soaking time in PB.
Excipient CPC-MPs
σb (MPa)
(Mean ± SD)
CPC-MPs-AL
σb (MPa)
(Mean ± SD)
Day 1 3 7 21 1 3 7 21
Stearylic alcohol 7 ± 2 7 ± 1 7 ± 1 9 ± 1 4 ± 1 7 ± 1 7 ± 1 6 ± 1
Stearic acid 7 ± 1 10 ± 2 11 ± 2 12 ± 3 8 ± 1 8 ± 1 9 ± 1 9 ± 1
Tristearin 6 ± 1 8 ± 1 9 ± 2 12 ± 3 7 ± 1 8 ± 1 8 ± 1 6 ± 3
Precirol® ATO5 9 ± 2 9 ± 1 13 ± 3 11 ± 2 6 ± 1 10 ± 1 10 ± 1 10 ± 3
Cutina® HR 8 ± 1 8 ± 2 8 ± 1 12 ± 2 8 ± 1 10 ± 1 10 ± 2 10 ± 2
None 12 ± 2 12 ± 1 9 ± 1 11 ± 3 nd nd nd nd
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9soaking times up to 21 days are reported in Table 4. The values re-
corded on the CPCs-MPs are signiﬁcantly diﬀerent (p < .05) compared
to CPC for soaking times ranging from 1 to 3 days, whereas did not
diﬀer signiﬁcantly from the reference samples (p > 0.05) for longer
times. The presence of AL-containing MPs did not alter the mechanical
properties of CPC-Cut_AL and CPC-Pre-AL even after 21 days of soaking,
while the σb values obtained from cements loaded with AL-containing
MPs of Aci, Alc and Ste evidenced a worsening of the mechanical
properties.
The fractured surfaces of CPCs-Cut and CPCs-Cut-AL after diﬀerent
times of soaking were reported in Fig. 10. The MPs are clearly em-
bedded into the cement matrix and keep unchanged their rounded
shape up to seven days of soaking. After this time, the MPs gradually
lose their morphology.
Fig. 10. Scanning electron microscopy performed
on fractured surfaces of CPCs samples containing
MPs-Cut and MPs-Cut-Al after diﬀerent times of
soaking.
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The alendronate released strongly inﬂuenced the hardening of the
cement near to the MPs: as an example, micrographs A and B show an
enlargement of the microstructure of the inorganic phase just around
the particles microparticles for CPCs-Cut-AL. The diﬀerent morpholo-
gies indicate the simultaneous presence of in situ formed CDHA (A) and
of residual α-TCP (B) up to seven days, whereas the presence of α-TCP
is not appreciable in the images from CPS-Cut, in agreement with the
results obtained from X-rays diﬀraction patterns.
3.5. Determination of alendronate release
The last step was the evaluation of AL release behaviour in PBS at
pH 7.2 for the microparticles and the cements. The pure AL completely
dissolved within few minutes, according to its great water solubility
(dissolution proﬁle not reported). The results (Fig. 11a) showed that the
drug encapsulation within the microparticles allowed to control the
release, due to the hydrophobicity of the excipients selected for the
preparation of the systems. The type of carrier slightly aﬀected the drug
release proﬁles only in the initial part (90 min): AL released from tris-
tearin (most lipophilic carrier) MPs was slower than from others MPs.
All the AL-MPs released more than 90% of the drug within 4 h. Precirol
ATO5 or Cutina HR microparticles, having slightly diﬀerent release
proﬁles, were then embedded into the cements to obtain a multi-com-
posite system. As expected, the release proﬁles of AL from the two
systems (Fig. 11b) were slower than that obtained from the MPs, evi-
dencing that both systems allowed to obtain a controlled release of the
drug at least for 21 days.
4. Conclusion
The results of this study demonstrate that Solid Lipid Microparticles
(MPs) of diﬀerent sizes produced by Spray Congealing technology can
be added into cement formulations up to 7% wt without worsening of
the setting properties of the ﬁnal materials. Furthermore, the capability
of MPs as carriers for controlled delivery of API was successfully proven
by using a Bisphosphonate, namely Alendronate, as a model drug.
Alendronate-containing CPCs could be of great interest for the delivery
of this therapeutic agent directly into the bone environment, in order to
minimize the numerous adverse side eﬀects of bisphosphonates sys-
temic administration. Until now, only low amount of AL has been
loaded into CPCs formulations, because of its ability to sequester cal-
cium from calcium phosphates, thus preventing the setting reaction of
bone cements. [43]. The approach followed in this study, that implies
the incorporation of the drug into MPs, hinders its direct contact with
the cement and allows to achieve an alendronate content 2.5-fold
greater than that previously reported for a cement of similar composi-
tion [18,19], without provoking signiﬁcant delay of the cementitious
reaction. The release of the highly water soluble drug from the MPs is
further controlled by their incorporation into CPC and as, a con-
sequence, a sustained release of the drug is provided. The obtained
results suggest the possibility of using Solid Lipid Microparticles em-
bedded in cement as drug delivery system for the local administration
of drugs to bone tissues.
In particular, the best results, in term of setting times and me-
chanical properties, were obtained using Precirol and Cutine as ecci-
pients. The results of this preliminary study could be improved by
loading higher AL content and the composite system tailored for the
local administration of a variety of drugs (i.e. antibiotics, anti-in-
ﬂammatory agents and anticancer drugs) to bone tissues. Furthermore,
biological properties of some selected composition are under evalua-
tion.
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